Managed Care

 

Determining the Cost-Effectiveness of a Computer-Based Smoking Cessation Intervention in Primary Care

MANAGED CARE July 2007. © MediMedia USA
Peer-Reviewed

Determining the Cost-Effectiveness of a Computer-Based Smoking Cessation Intervention in Primary Care

Meredith Y. Smith, PhD
Purdue Pharma, Stamford, Conn.
Jerry Cromwell, PhD
Research Triangle Institute, Research Triangle Park, N.C.
Judith DePue, EdD
Miriam Hospital/Brown Medical School, Providence, R.I.
Bonnie Spring, PhD
Northwestern University, Chicago, Ill.
William Redd, PhD
Mount Sinai School of Medicine, New York, N.Y.
MANAGED CARE July 2007. ©MediMedia USA

Meredith Y. Smith, PhD

Purdue Pharma, Stamford, Conn.

Jerry Cromwell, PhD

Research Triangle Institute, Research Triangle Park, N.C.

Judith DePue, EdD

Miriam Hospital/Brown Medical School, Providence, R.I.

Bonnie Spring, PhD

Northwestern University, Chicago, Ill.

William Redd, PhD

Mount Sinai School of Medicine, New York, N.Y.

Marina Unrod, PhD

Mount Sinai School of Medicine, New York, N.Y.

Abstract

Purpose: To evaluate the incremental effectiveness and cost-effectiveness of a staged-based, computerized smoking cessation intervention relative to standard care in an urban managed care network of primary care physicians.

Design: Decision-analytic model based on results of a randomized clinical trial.

Methodology: Patient outcomes and cost estimates were derived from clinical trial data. Effectiveness was measured in terms of 7-day point-prevalence abstinence at 6 months post-intervention. Quality-adjusted life years (QALYs) and cost-effectiveness (CE) were calculated, with CE measured as cost per patient per life year saved and per quality-adjusted life years saved. CE estimates were adjusted to account for partial behavior change as measured in terms of progression in stage of readiness to quit. Sensitivity analyses were conducted to evaluate the robustness of key model assumptions.

Principal findings: Intervention patients were 1.77 times more likely to be smoke-free at 6 months follow-up than those in standard care (p=.078). The intervention generated an additional 3.24 quitters per year. Annualized incremental costs were $5,570 per primary care practice, and $40.83 per smoker. The mean incremental cost-effectiveness ratio was $1,174 per life year saved ($869 per QALY). When the intervention impact on progression in stage of readiness to quit was also considered, the mean incremental cost-effectiveness ratio declined to $999 per life year saved ($739 per QALY).

Conclusions: From a physician's practice perspective, the stage-based computer tailored intervention was cost-effective relative to standard care. Incorporation of partial behavior change into the model further enhanced favorability of the cost-effectiveness ratio.

Key words: cost-effectiveness, smoking cessation, primary care, expert system, stages of change

The research was conducted at the Mount Sinai School of Medicine, New York, N.Y.

Corresponding author:
Meredith Y. Smith, MPA, PhD
Adjunct Assistant Professor, Mount Sinai School of Medicine
Director, Risk Management & Health Policy, Purdue Pharma
One Stamford Forum, Stamford, CT 06901-3431, USA

Meetings

2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
6th Semi-Annual Diagnostic Coverage and Reimbursement Conference Boston December 4–5, 2014
Customer Analytics & Engagement in Health Insurance Chicago December 4–5, 2014
Pharmaceutical and Biotech Clinical Quality Assurance Conference Alexandria, VA December 4–5, 2014
9th Semi-Annual Medical Device Coverage and Reimbursement Conference San Diego December 5, 2014
8th Annual Medical Device Clinical Trials Conference Chicago December 8–9, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015